Technical Analysis for ORTX - Orchard Therapeutics plc

Grade Last Price % Change Price Change
grade C 17.79 -3.89% -0.72
ORTX closed down 3.89 percent on Thursday, April 18, 2019, on 1.16 times normal volume. It was able to find support at its 50 day moving average.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Down
See historical ORTX trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Fell Below 20 DMA Bearish -3.89%
Down 3 Days in a Row Weakness -3.89%
MACD Bearish Signal Line Cross Bearish -7.63%
Calm After Storm Range Contraction -7.63%

Older signals for ORTX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:

Profile
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Orchard’s advanced portfolio of autologous ex vivo gene therapies targets serious and life-threatening rare diseases, initially primary immune deficiencies, neurometabolic disorders and hemoglobinopathies.
Biotechnology Health Biopharmaceutical Nature Therapy Hemoglobinopathies
Is ORTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Apr 15 Orchard Therapeutics Announces Presentation of Clinical Proof-of-Concept for OTL-300 for the Treatment of Transfusion-Dependent Beta-Thalassemia at the 22nd American Society of Gene & Cell Therapy Annual Meeting
Apr 5 The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership
Mar 27 Orchard gene therapy shows positive effect MLD study
Mar 27 Will Orchard Therapeutics Continue to Surge Higher?
Mar 27 The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO
Mar 27 Orchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLD
Mar 21 Orchard Therapeutics PLC (ORTX) CEO Mark Rothera on Q4 2018 Results - Earnings Call Transcript
Mar 21 The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering
Mar 21 Orchard Therapeutics reports FY results
Mar 21 Orchard Therapeutics Reports 2018 Financial Results and Reviews Recent Business Highlights
See more ORTX news...
Indicators
Indicator Value
52 Week High 21.64
52 Week Low 8.65
Average Volume 112,757
200-Day Moving Average 0.0
50-Day Moving Average 17.0444
20-Day Moving Average 18.821
10-Day Moving Average 19.406
Average True Range 1.597
ADX 36.74
+DI 19.24
-DI 17.5242
Chandelier Exit (Long, 3 ATRs ) 16.849
Chandelier Exit (Short, 3 ATRs ) 21.051
Upper Bollinger Band 21.1147
Lower Bollinger Band 16.5273
Percent B (%b) 0.28
BandWidth 24.373838
MACD Line 0.6279
MACD Signal Line 0.8702
MACD Histogram -0.2423
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.48
Resistance 3 (R3) 20.47 19.55 20.04
Resistance 2 (R2) 19.55 18.87 19.56 19.89
Resistance 1 (R1) 18.67 18.44 18.22 18.69 19.74
Pivot Point 17.76 17.76 17.53 17.77 17.76
Support 1 (S1) 16.88 17.07 16.42 16.89 15.84
Support 2 (S2) 15.96 16.65 15.97 15.69
Support 3 (S3) 15.08 15.96 15.54
Support 4 (S4) 15.10